Join
Live feed
·
PRReleasevia Quantisnow
INmune Bio Inc. logo

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
INMB· INmune Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INMB (INmune Bio Inc.) and more on Quantisnow.